Mercaptoethylguanidine
Alternative Names: MEGLatest Information Update: 24 Oct 2021
At a glance
- Originator Nonindustrial source
- Developer Inotek Pharmaceuticals; Nonindustrial source
- Class Guanidines; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide synthase type II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Rheumatoid arthritis; Shock; Systemic inflammatory response syndrome
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 17 Apr 2002 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 17 Apr 2002 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)